Clinical Trial Update: Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib as add-on therapy for relapsing neuromyelitis optica spectrum disorder completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 2 | Status: COMPLETED